BAXTER INTERNATIONAL INC reported revenue of $2.96B for the period ended 2026-06-30, +5.3% year on year. Net income was $0.13B, a 4.3% net margin on a 34.9% gross margin. The largest revenue line is Infusion Therapies And Platforms at 59% of the total. Free cash flow for the period was $0.17B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $2.96B | +5.3% |
| Gross profit | $1.03B | — |
| Operating income | $0.22B | — |
| Net income | $0.13B | +38.5% |
| Gross margin | 34.9% | Net margin 4.3% |
| Revenue Q/Q | +9.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| Infusion Therapies And Platforms | $1.75B | 59.0% |
| Healthcare Systems And Technologies | $0.80B | 27.1% |
| Advanced Surgery | $0.33B | 11.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $1.93B | 65.1% |
| R&D | $0.13B | 4.4% |
| SG&A | $0.73B | 24.8% |
| Tax & other | $0.09B | 3.1% |
| Item | Amount |
|---|---|
| Total assets | $19.79B |
| Total liabilities | $13.61B |
| Shareholders' equity | $6.18B |
| Equity / assets | 31.2% |
| Operating cash flow | $0.28B |
| Capital expenditure | $0.12B |
| Free cash flow | $0.17B |
| Cash conversion (OCF / net income) | 226% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
BDX ・ BRK.B ・ BBY ・ TECH ・ BIIB ・ BLK ・ BX ・ XYZ ・ BNY ・ BA ・ BKNG ・ BSX
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies